HGH Fragment 176-191 vs PT-141
Head-to-head comparison of HGH Fragment 176-191 (Human Growth Hormone Fragment 176-191) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HGH Fragment 176-191 | PT-141 |
|---|---|---|
| Category | Weight Management | Performance |
| Full Name | Human Growth Hormone Fragment 176-191 | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 1817.12 g/mol | 1,025.2 Da |
| Half-Life | ~30 minutes | ~2.7 hours |
| Amino Acids | 16 | 7 |
| Typical Dose | — | 1.75 mg |
| Route | — | SC |
| Purity | >98% | — |
| Studies Count | 45 | 178 |
| Research Status | Active Research | FDA Approved |
HGH Fragment 176-191 Benefits
- ✓Targeted fat loss, no blood sugar impact, no IGF-1 elevation, inhibits lipogenesis, stimulates lipolysis, improved body composition
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
HGH Fragment 176-191 Dosing
250-500 mcg subcutaneously 1-2 times daily on empty stomach. 12-16 week cycles typical in research.
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
HGH Fragment 176-191 Side Effects
- ⚠Injection site irritation, headache, drowsiness. Does not affect blood sugar, insulin sensitivity, or elevate IGF-1.
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
HGH Fragment 176-191
This 16-amino-acid fragment specifically targets adipose tissue via beta-3 adrenergic receptors. Works through a GH-receptor-independent pathway, explaining selective fat-loss properties without growth-promoting effects.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.